NVST — Envista Holdings Corp stock price, charts and financials

NYSE·Healthcare·Medical - Instruments & Supplies·USA

Latest market price

27.96

+0.59+2.16%

Overview Short InterestFilings

NVSTQT52Envista Holdings Corp·NYSE

Overview Short InterestFilings

27.96+2.16%

Earnings

Up 2.2% — Reported earnings — EPS beat by 15%, revenue beat by 4%.

High confidence

Loading chart...

Signal & projected range

QT Score downgradeHistorical pattern — not a prediction

Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

ICUI-0.57%$171.96 MMSI+0.34%$85.82 STVN-4.57%$19.65 BLCO-0.54%$16.68 TFX+0.30%$140.12 XRAY+0.99%$14.27 PLSE+1.17%$38.17 RGEN+1.85%$149.78

Snapshot

Index	-	P/E	68.20	EPS (ttm)	0.41	Insider Own	1.83%	Shs Outstand	162.73M	Perf Week	3.71%

Market Cap	4.55B	Forward P/E	17.80	EPS next Y	1.57	Insider Trans	-0.19%	Shs Float	162.02M	Perf Month	1.64%

Enterprise Value	5.02B	PEG	7.21	EPS next Q	-	Inst Own	-	Short Float	5.78%	Perf Quarter	8.33%

Income	68.00M	P/S	1.62	EPS this Y	248.99%	Inst Trans	-	Short Ratio	2.99	Perf Half Y	20.21%

Sales	2.81B	P/B	1.48	EPS next Y	9.76%	ROA	1.21%	Short Interest	9.36M	Perf YTD	28.79%

Book/sh	18.93	P/C	4.20	EPS next 5Y	9.46%	ROE	2.18%	52W High	30.42 -8.09%	Perf Year	34.23%

Cash/sh	6.66	P/FCF	20.18	EPS past 3/5Y	-40.66% 1.49%	ROIC	1.78%	52W Low	18.77 48.96%	Perf 3Y	-19.40%

Dividend Est.	-	EV/EBITDA	14.46	Sales past 3/5Y	1.92% 7.11%	Gross Margin	55.14%	Volatility	3.37% 2.98%	Perf 5Y	-33.30%

Dividend TTM	-	EV/Sales	1.79	EPS Y/Y TTM	106.31%	Oper. Margin	9.04%	ATR (14)	0.85	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	2.06	Sales Y/Y TTM	11.87%	Profit Margin	2.41%	RSI (14)	61.34	Recom	2.68

Dividend Gr. 3/5Y	-	Current Ratio	2.44	EPS Q/Q	50.00%	SMA20	4.52%	Beta	0.85	Target Price	29.25

Payout	0.00%	Debt/Eq	0.50	Sales Q/Q	14.42%	SMA50	9.07%	Rel Volume	0.99	Prev Close	27.37

Employees	12,000	LT Debt/Eq	0.50	Earnings	Aug 05	SMA200	14.53%	Avg Volume	3.19M	Price	27.96

IPO Date	Sep 18, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	15.36% 3.74%	Net Debt/EBITDA	1.46	Volume	3,166,797	Change	2.16%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-29-26	Reiterated	Piper Sandler	Neutral	$25 → $26
Jul-08-26	Initiated	BMO Capital	Market Perform	$27
Jun-11-26	Reiterated	Barclays	Overweight	$24 → $32
May-07-26	Reiterated	Robert W. Baird		$30 → $31
May-07-26	Reiterated	Evercore ISI Group	Outperform	$30 → $33
Apr-08-26	Reiterated	Evercore ISI Group	Outperform	$32 → $30
Feb-06-26	Reiterated	Robert W. Baird		$27 → $30
Feb-06-26	Reiterated	Morgan Stanley	Equal Weight	$18 → $19
Feb-06-26	Reiterated	Evercore ISI	Outperform	$26 → $32
Feb-06-26	Reiterated	Stifel Nicolaus	Buy	$27 → $31

Latest News

Jul-30-26

Jul-30-2610:01AM

Envista (NVST) Stock Jumps 5.2%: Will It Continue to Soar?zacks.com

Jul-29-26

Jul-29-2601:17PM

Piper Sandler Maintains Neutral on Envista Holdings, Raises Price Target to $26Benzinga

Jul-28-26

Jul-28-2604:15PM

Envista to Host Investor Day on September 17, 2026prnewswire.com

Jul-17-26

Jul-17-2610:50AM

Envista Holdings Corp (NYSE:NVST) Is a Decent Value Stock with Strong Growth ProspectsChartMill

Jul-14-26

Jul-14-2609:03AM

1 Profitable Stock with Impressive Fundamentals and 2 We QuestionYahoo

Jul-09-26

Jul-09-2611:31AM

Does NVST Stock Still Deserve a Place in Your Portfolio?zacks.com

Jul-07-26

Jul-07-2608:15PM

Envista Schedules Second Quarter 2026 Earnings CallYahoo

Jun-19-26

Jun-19-2612:13PM

NVST Stock Rallies 37.1% in a Year: What's Behind the Drive?Yahoo

Jun-11-26

Jun-11-2610:46AM

Barclays Maintains Overweight on Envista Holdings, Lowers Price Target to $32Benzinga

Company

Envista Holdings Corporation is an enterprise dedicated to the development and distribution of a comprehensive range of dental solutions. These offerings are crucial for the identification, therapeutic intervention, and preventative care of diverse oral health issues, specifically addressing the teeth, gingiva (gums), and their supporting bone structures. The company's principal location is in Brea, California, and it maintains a workforce comprising 12,800 full-time personnel. The firm organizes its business activities into two main divisions: "Specialty Products & Technologies" and "Equipment & Consumables." The Specialty Products & Technologies division concentrates on the creation, fabrication, and promotion of sophisticated dental implant systems, advanced prosthetic devices, and their associated digital treatment software and technological advancements. This segment also provides orthodontic remedies, including bracket systems, clear aligners, and various items for dental laboratories. Conversely, the Equipment & Consumables division is responsible for conceptualizing, producing, and bringing to market a wide array of dental apparatus and vital supplies intended for professional dental clinics. This extensive catalog includes digital imaging instruments, specialized software, and visual or magnification systems; patient treatment units and other essential fixtures for dental practices; complete endodontic kits along with their complementary consumable items; materials and tools for restorative dentistry; rotary cutting tools (burs); impression-making compounds; adhesive agents and dental cements; and products designed for infection control.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	2,809	2,720	2,511	2,567	2,569	2,509	1,929	2,285	2,845
Cost of Goods Sold Incl. D&A	1,260	1,223	1,119	1,116	1,081	1,047	856	933	1,235
Gross Profit	1,548	1,496	1,392	1,451	1,488	1,462	1,073	1,352	1,610
Selling, General and Administrative Excl. Other	1,176	1,157	1,136	1,029	1,028	990	859	970	1,113
Research and Development	118	114	99	94	100	101	87	133	172
Other Operating Expense	0	0	1,195	296	41	65	84	13	26
Operating Income	255	226	-1,038	32	319	306	44	236	298
Interest Expense	20	37	46	63	38	54	63	4	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-34	-12	0	-23	3	2	-1	2	3
Net Income Before Taxes	201	177	-1,085	-55	284	255	-20	234	301
Income Taxes	133	130	34	45	46	-9	-62	50	70
Consolidated Net Income	68	47	-1,119	-100	243	341	33	218	231
Net Income From Continuing Operations	68	47	-1,119	-100	238	264	42	184	231
Net Income	68	47	-1,119	-100	243	341	33	218	231
EPS (Recurring)	0.42	0.28	-6.50	-0.60	1.46	1.63	0.27	1.35	1.80
EPS (Basic, Before Extraordinaries)	0.42	0.28	-6.50	-0.60	1.46	1.63	0.27	1.35	1.80
EPS (Diluted)	0.41	0.28	-6.50	-0.60	1.34	1.48	0.26	1.35	1.80
EBITDA	347	330	280	463	498	496	260	377	455
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	68.20	77.54	—	—	25.13	30.45	129.73	21.96	—
Price To Sales Ratio	1.63	1.34	1.32	1.57	2.14	2.89	2.80	1.76	—
Gross Margin	55.11	55.00	55.44	56.53	57.92	58.27	55.62	59.17	56.59
Operating Margin	9.08	8.31	-41.34	1.25	12.42	12.20	2.28	10.33	10.47
Net Margin	2.42	1.73	-44.56	-3.90	9.46	13.59	1.71	9.54	8.12
Shares Outstanding	164	168	172	167	163	161	160	136	155
Market Capitalization	4,585	3,647	3,318	4,018	5,488	7,255	5,397	4,031	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Reis Mischa	SVP, Strategy & Bus. Dev.	Feb 10 '26	Option Exercise	17.25	9,675	166,916	38,016	Feb 11
Reis Mischa	SVP, Strategy & Bus. Dev.	Feb 10 '26	Sale	30.00	5,634	169,020	32,382	Feb 11
Reis Mischa	SVP, Strategy & Bus. Dev.	Aug 25 '25	Sale	21.60	15,000	324,000	32,382	Aug 27
Keel Paul A	Chief Executive Officer	Aug 13 '24	Buy	16.87	30,000	506,100	402,605	Aug 14
Hammes Eric D.	Chief Financial Officer	Aug 12 '24	Buy	16.33	24,532	400,608	24,532	Aug 13
Conley Eric	SVP, Orthodontics	Nov 16 '23	Buy	22.89	2,185	50,015	47,376	Nov 20
Nance Mark E	General Counsel	Nov 08 '23	Buy	21.75	5,000	108,750	39,042	Nov 09
Aghdaei Amir	Chief Executive Officer	Nov 06 '23	Buy	21.53	10,000	215,254	295,362	Nov 07
Keller Stephen	Principal Financial Officer	Nov 06 '23	Buy	21.53	2,000	43,060	13,070	Nov 07
Yu Howard H	Chief Financial Officer	Feb 28 '23	Sale	37.90	10,016	379,606	45,865	Mar 01
Yu Howard H	Chief Financial Officer	Nov 17 '22	Sale	36.55	657	24,013	51,106	Nov 21
Yu Howard H	Chief Financial Officer	Apr 18 '22	Sale	45.73	5,341	244,244	52,411	Apr 20
Aghdaei Amir	Chief Executive Officer	Mar 29 '22	Sale	51.50	3,801	195,752	364,779	Mar 31
Yu Howard H	Chief Financial Officer	Mar 21 '22	Option Exercise	21.76	4,786	104,144	59,682	Mar 22
Reis Mischa	SVP, Strategy & Bus. Dev.	Mar 18 '22	Sale	50.00	10,092	504,600	31,327	Mar 22

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.